anti-BCMA and CD19 CAR-T cells

Anti-BCMA and CD19 CAR-T cells represent a novel immunotherapy strategy involving genetically engineered T cells that express chimeric antigen receptors (CARs) designed to target two distinct antigens: B-cell maturation antigen (BCMA) and CD19. This dual-targeting approach aims to enhance anti-tumor efficacy and overcome mechanisms of resistance, such as antigen escape, which can occur with single-target CAR-T therapies. BCMA is predominantly expressed on plasma cells and multiple myeloma cells, making it a key target for multiple myeloma. CD19 is widely expressed on B-cells and B-cell malignancies, including non-Hodgkin lymphoma. By targeting both antigens, these CAR-T cells are intended to provide broader coverage and potentially deeper, more durable responses in patients with hematological malignancies. The T cells are typically harvested from the patient (autologous) or a healthy donor (allogeneic), modified ex vivo to express the CARs, expanded, and then reinfused into the patient. This process leverages the patient's own immune system to specifically recognize and eliminate cancer cells.

Other names

combined anti-BCMA and anti-CD19 CAR-T cell therapydual-target CAR T-cell therapybispecific BC19 CAR T cellsCD19/BCMA CAR Tcells therapyAnti CD19 and anti BCMA CAR-T cell therapyAntiCD19/BCMA CART cell therapy Yake BiotechnologyCD19/BCMA CAR Tcells injection